Record-breaking pharma M&A value disguises plummeting deal-making activity
Abundant biotech funding seems to be empowering small- and medium-sized IP rights holders and driving down acquisition and licensing volume
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.